MedTrace Logo

Dose-finding Study With Lu AA24530 in Major Depressive Disorder

NCT00599911 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 652

Last updated 2016-11-08

No results posted yet for this study

Summary

The primary purpose of this study is to assess the efficacy in treating patients with Major Depressive Disorder of one or more doses of Lu AA24530 relative to placebo

Conditions

Interventions

DRUG

Lu AA24530

per oral, once daily for 6 weeks

DRUG

Duloxetine

per oral, once daily for 6 weeks

DRUG

Placebo

per oral, once daily for 6 weeks

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-03-31
Completion
2009-04-30

Countries

  • Australia
  • Austria
  • Belgium
  • Canada
  • Czechia
  • Finland
  • France
  • India
  • Lithuania
  • Malaysia
  • Norway
  • Philippines
  • Russia
  • Serbia
  • South Korea
  • Sweden
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00599911 on ClinicalTrials.gov